Clinical Trial Update: A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF) [Phase 1]

View source ↗

Summary

Gilead Sciences has withdrawn its Phase 1 trial of GS-9411 in cystic fibrosis patients, which was evaluating safety, tolerability, and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• GS-9411

Snippet

Sponsor: Gilead Sciences | Conditions: Cystic Fibrosis, Mucociliary Clearance | Phase 1 | Status: WITHDRAWN